Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Down 50.2% in June

Posted by George Bondi on Jul 15th, 2026

Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 3,507,190 shares, a drop of 50.2% from the June 15th total of 7,042,866 shares. Based on an average daily trading volume, of 3,393,103 shares, the short-interest ratio is currently 1.0 days. Approximately 3.0% of the shares of the company are sold short.

Hedge Funds Weigh In On Cytek Biosciences

A number of hedge funds have recently made changes to their positions in CTKB. Caitong International Asset Management Co. Ltd grew its stake in Cytek Biosciences by 86.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,144 shares of the company’s stock worth $26,000 after purchasing an additional 2,388 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in Cytek Biosciences by 99.6% in the fourth quarter. SBI Securities Co. Ltd. now owns 5,010 shares of the company’s stock valued at $25,000 after buying an additional 2,500 shares during the last quarter. Intech Investment Management LLC raised its stake in Cytek Biosciences by 6.7% during the fourth quarter. Intech Investment Management LLC now owns 51,740 shares of the company’s stock valued at $261,000 after buying an additional 3,242 shares in the last quarter. Deutsche Bank AG raised its stake in Cytek Biosciences by 4.6% during the fourth quarter. Deutsche Bank AG now owns 93,139 shares of the company’s stock valued at $470,000 after buying an additional 4,119 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in Cytek Biosciences by 150.9% during the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after buying an additional 4,343 shares during the last quarter. Hedge funds and other institutional investors own 69.46% of the company’s stock.

Cytek Biosciences Stock Up 0.3%

Shares of NASDAQ CTKB traded up $0.01 during midday trading on Wednesday, hitting $4.63. The stock had a trading volume of 239,358 shares, compared to its average volume of 1,060,305. Cytek Biosciences has a 1-year low of $3.09 and a 1-year high of $6.18. The company has a market capitalization of $598.56 million, a price-to-earnings ratio of -8.15 and a beta of 1.17. The company has a fifty day moving average price of $4.17 and a 200 day moving average price of $4.52.

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). Cytek Biosciences had a negative return on equity of 10.07% and a negative net margin of 36.25%.The business had revenue of $44.13 million for the quarter, compared to analyst estimates of $44.23 million. On average, research analysts forecast that Cytek Biosciences will post -0.21 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CTKB. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Wednesday, June 24th. Morgan Stanley reduced their price objective on Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Stephens decreased their target price on shares of Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cytek Biosciences currently has a consensus rating of “Hold” and a consensus target price of $5.69.

Check Out Our Latest Research Report on CTKB

About Cytek Biosciences

(Get Free Report)

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.